NOF Corp (NOF) is a manufacturer of oleo, functional and specialty chemicals, polymers, explosive and propulsion products, function food and life science products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

NOF is actively engaged in research and development across various business segments, including functional chemicals, pharmaceuticals, medical care, health, and chemicals. The company is focusing on developing unique technologies and leveraging its comprehensive strength to respond to changes in the chemical industry and social needs. In new growth fields, NOF is promoting R&D through its research departments and collaborations with industry, academia, and government. Key initiatives include developing high-value-added products in functional chemicals, expanding plant-based ingredients in healthcare, and advancing materials for electronics, automotive, and construction fields. In pharmaceuticals, the company is working on biocompatible materials and drug delivery systems. In chemicals, the focus is on industrial explosives and space-related products. Corporate research is directed towards next-generation materials and technologies, with an emphasis on medical care and regenerative medicine. The R&D units of NOF include the Advanced Technology Research Institute and the Nano Medicine Innovation Center. The Advanced Technology Research Institute is responsible for researching next-generation materials and technologies, while the Nano Medicine Innovation Center focuses on cutting-edge medical care and regenerative medicine. Additionally, the company has established a collaborative research lab with the AIST Group to promote open innovation and the creation of next-generation products. In FY2025, the company incurred an expense of JPY7,031 million on R&D which as a percentage of revenue stood at 3% and grew 11% YoY.